What are the different phenotypes of polycystic ovary syndrome (PCOS) and how should each be managed?

PCOS Phenotypes and Management

PCOS should be diagnosed using the Rotterdam criteria, which identifies four distinct phenotypes based on the presence of two of three features: hyperandrogenism, ovulatory dysfunction, and polycystic ovarian morphology (PCOM), with management tailored to the specific phenotype and its associated metabolic and reproductive risks 1.

The Four PCOS Phenotypes

Based on the Rotterdam criteria, PCOS presents in four distinct phenotypes with varying metabolic and reproductive risks 2, 3:

• Phenotype A (Classic PCOS): Hyperandrogenism + Ovulatory dysfunction + PCOM

  • Highest metabolic risk with most pronounced insulin resistance, dyslipidemia, and metabolic syndrome prevalence 2, 4
  • Represents approximately 30% of PCOS patients with elevated BP, BMI, HOMA-IR, and triglycerides 5

• Phenotype B (Non-PCO PCOS): Hyperandrogenism + Ovulatory dysfunction (without PCOM)

  • Similar high metabolic risk to Phenotype A 2
  • Shares insulin resistance and cardiovascular risk profile with Phenotype A 4

• Phenotype C (Ovulatory PCOS): Hyperandrogenism + PCOM (with regular ovulation)

  • Intermediate metabolic risk despite ovulatory function 2
  • Metabolic abnormalities driven primarily by androgen excess 2
  • Represents approximately 43% of patients with higher LH:FSH, DHEAS, androstenedione, and SHBG 5

• Phenotype D (Non-hyperandrogenic PCOS): Ovulatory dysfunction + PCOM (without hyperandrogenism)

  • Mildest hormonal and metabolic profile 2
  • Lowest cardiovascular risk among all phenotypes 4

Phenotype-Specific Management Approach

First-Line Management for All Phenotypes

Lifestyle interventions constitute first-line therapy across all phenotypes, with 5-10% weight loss as the target 6. This includes:

• Hypocaloric diet (500-700 kcal/day deficit) focusing on low glycemic index foods 6
• 150 minutes/week of moderate-high intensity aerobic exercise 6
• Behavioral interventions combined with diet and exercise 6

Critical caveat: The metabolic risk differences between phenotypes are largely driven by obesity, making weight management particularly crucial for Phenotypes A and B 4. However, emerging evidence suggests that universal weight loss advice fails to reflect the biological diversity of PCOS, particularly in lean patients with Phenotype C or D 7.

Management of Menstrual Irregularity

Hormonal contraceptives are first-line treatment for menstrual irregularities in both adults and adolescents 6, 1:

• Use standard contraceptive screening criteria from the general population 6
• Second-line options include metformin, cyproterone acetate, or drospirenone 6
• For amenorrheic women, progesterone can induce regular withdrawal bleeds 6

This applies primarily to Phenotypes A, B, and D where ovulatory dysfunction is present.

Management of Hyperandrogenism (Phenotypes A, B, C)

For hirsutism and acne, photoepilation and topical eflornithine are first-line treatments, with hormonal contraceptives as the primary pharmacological option 6, 1:

• Assess hirsutism using Ferriman-Gallwey score and acne using Ludwig visual score 6
• Hormonal contraceptives address both menstrual irregularity and hyperandrogenic symptoms simultaneously 1
• Antiandrogens can be added as second-line therapy 6

Metabolic Management (Primarily Phenotypes A and B)

Metformin is beneficial for metabolic and glycemic abnormalities and menstrual irregularities, but has limited benefit for hirsutism, acne, or infertility 1:

• Consider metformin after 6 months of lifestyle intervention if weight loss targets are not met 6
• Screen for diabetes risk using OGTT, particularly in Phenotypes A and B 1
• Monitor for metabolic syndrome, hepatic steatosis, and cardiovascular risk factors 3
• Bariatric surgery may be considered in obese women if lifestyle interventions fail 6

Important limitation: Thiazolidinediones have an unfavorable risk-benefit ratio and are not recommended 1.

Fertility Management (Phenotypes A, B, D)

Clomiphene citrate remains first-line therapy for infertility 1:

• Lifestyle modifications should precede or accompany fertility treatment 1
• Aromatase inhibitors are alternative options 8
• Metformin has limited benefit for fertility outcomes 1

Adolescent-Specific Considerations

In adolescents, avoid using PCOM as an independent diagnostic criterion, and emphasize hyperandrogenism as central to diagnosis 6, 1:

• Ultrasound has limited diagnostic value in this population 6
• Do not use anti-Müllerian hormone for diagnosis in adolescents 6
• Treatment options include hormonal contraceptives and metformin 1
• Define oligo/amenorrhea carefully using age-appropriate criteria 6

Diagnostic Workup by Phenotype

To establish phenotype, assess:

• Hyperandrogenism: Total or free testosterone, or free androgen index (total testosterone/SHBG × 100) 6; clinical assessment using Ferriman-Gallwey score for hirsutism 6
• Ovulatory dysfunction: Menstrual history, progesterone levels
• PCOM: Transvaginal ultrasound in adults (not recommended as sole criterion in adolescents) 6

Do not use anti-Müllerian hormone for routine PCOS diagnosis in adults, though one guideline suggests it may be useful 6.

Key Clinical Pitfalls

• Phenotypes A and B require aggressive metabolic screening and intervention due to highest cardiovascular and diabetes risk 2, 4
• Lean PCOS patients (often Phenotype C) may not benefit from standard weight loss advice and require phenotype-specific approaches 7, 5
• Phenotype D is often underdiagnosed due to absence of hyperandrogenism but still requires management of ovulatory dysfunction 2
• Phenotypes can evolve over time with weight gain, requiring reassessment 8
• Androstenedione and 17-hydroxyprogesterone are important in identifying the reproductive phenotype and should not be overlooked 5